Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor update to the documentation/version history.SummaryDifference0.0%

- Check9 days agoChange DetectedA new funding identifier '2015 ( U.S. NIH Grant/Contract )' was added next to the study identifiers, indicating NIH support for the trial. The addition provides funding context but does not change the study design or eligibility.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page's revision metadata was updated to version v3.6.5 with August 2026 timestamps, indicating a maintenance update rather than substantive changes to study content.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page's revision was updated from v3.6.3 to v3.6.4. This appears to be a minor maintenance update that does not change study data or content.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page now displays a newer revision tag (v3.6.3) replacing the previous v3.6.0, indicating a minor backend/template update without altering study information.SummaryDifference0.0%

- Check81 days agoChange DetectedThe page now indicates recruitment is closed. It also adds new guidance sections such as How to Read a Study Record, Common Questions, and How to Join a Study, and updates the Intervention/Treatment area along with a revision label v3.6.0.SummaryDifference0.3%

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.